Abiopharma

🔍 Ladone Mary Kay (Director)

Company: NOVANTA INC (NOVT)

Report Date: 2026-01-02

Detailed Transactions and Holdings:

• Acquired 1,325 shares of Common Stock (Direct)
  Date: 2026-01-02 | Code: M | equity_swap_involved: 0 | shares_owned_after: 1,897.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 1,325 shares of Restricted Stock Units (Derivative)
  Date: 2026-01-02 | Code: M | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F1, F1, F1
• Acquired 1,799 shares of Restricted Stock Units (Derivative)
  Date: 2026-01-02 | Code: A | equity_swap_involved: 0 | shares_owned_after: 1,799.00 | transaction_form_type: 4 | Footnotes: F2, F3, F3

Footnotes:

• F1: Each Restricted Stock Unit ("RSU") was the economic equivalent of one Novanta Inc. common share. On January 2, 2026, the RSUs were settled in Novanta Inc. common shares.
• F2: Each Restricted Stock Unit represents the right to receive one Novanta Inc. common share on the first anniversary of the Grant Date (or, if such date is not a business day, on the first business day immediately following the first anniversary of the Grant Date).
• F3: The Restricted Stock Units were fully vested and non-forfeitable on the Grant Date.
• REMARKS: Power of Attorney on file